Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Lawmakers Urge Expanded Fertility Treatment Support via Coverage, Subsidies
May 28, 2021
- Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Next Drug Distribution Confab Set for July 2 after Bid-Rigging Verdicts
May 27, 2021
- Trintellix Braced for Price Cut as Chuikyo OKs CEA Results, Coralan Intact
May 27, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
- LDP Economic Growth HQ Hammers Out Proposal for Honebuto Paper
May 26, 2021
- Moderna Vaccine Likely to Be Used for Workplace Vaccination
May 26, 2021
- Japan Eyes Pfizer Vaccine Use in Younger People, Longer Refrigerator Storage
May 26, 2021
- 2nd Humira Biosimilar, 1st NovoRapid Follow-On Gets Japan Listing on May 26
May 25, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- MHLW Grants Orphan Status to Eculizumab, 2 More APIs
May 25, 2021
- Japan Hails Janssen Vaccine Submission as New Option: Spokesman
May 25, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- PMDA Reviewing New Safety Risk for Keytruda
May 24, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…